ACADIA Pharmaceuticals Inc.
As of Oct 22, 2026, ACADIA Pharmaceuticals is in Stage 3, the topping phase, now in week 3 (since Oct 2, 2026). It closed at $20.31, 33.6% below its 52-week high and below its 200-day average, which is falling.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ACAD early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ACAD among Biotechnology200th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …200 | ACAD | Stage 3 · wk 3 | 50 | −20.1% |
ACADIA Pharmaceuticals: quick answers
What stage is ACADIA Pharmaceuticals in?
As of Oct 22, 2026, ACADIA Pharmaceuticals (ACAD) is in Stage 3, the topping phase. It entered Stage 3 on Oct 2, 2026 and is in week 3. What the four stages mean
Is ACADIA Pharmaceuticals in an uptrend?
Its uptrend has stalled. ACADIA Pharmaceuticals is in Stage 3, the topping phase that follows an advance. It trades 14.9% below its 200-day average, which is falling.
How far is ACADIA Pharmaceuticals from its 52-week high?
ACADIA Pharmaceuticals closed at $20.31 on Oct 22, 2026, 33.6% below its 52-week high of $30.57. Its 52-week low is $18.62.
How has ACADIA Pharmaceuticals performed over the past year?
As of Oct 22, 2026, ACADIA Pharmaceuticals is down 4.5% over the past year and down 22.7% so far in 2026.
Which sector and industry is ACADIA Pharmaceuticals in?
ACADIA Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.